Dual-Marker Platelet Reactivity Assessment for Residual Thrombotic Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for evaluating residual platelet thrombotic potential in patients undergoing antiplatelet treatment, particularly with clopidogrel, are inadequate as they fail to accurately distinguish between responders and non-responders, leading to a significant percentage of patients experiencing further thrombotic events despite effective pharmacological treatment.
Innovation Solution
A method involving the simultaneous determination of vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) status and platelet tissue factor (TF) expression in a blood sample, using flow cytometry and specific monoclonal antibodies, to improve the evaluation of residual platelet reactivity and predict adverse cardiovascular events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single-marker methods (VASP or TF alone) are used to evaluate platelet reactivity, then the evaluation process is simple, but the accuracy in distinguishing responders from non-responders is insufficient
Solution Approach 1:
The patent combines two distinct evaluation markers (VASP phosphorylation status and tissue factor expression) into a single dual-parameter assessment system. This merging allows simultaneous measurement of both markers in the same patient sample, achieving more accurate differentiation between responders and non-responders while maintaining practical feasibility through standardized flow cytometry protocols
2Reliability
If conventional single-parameter evaluation methods are used, then the monitoring process is straightforward, but the ability to identify patients with residual thrombotic risk is limited
Solution Approach 1:
The patent establishes a feedback mechanism where the dual-parameter profile (VASP-P status and TF expression levels) provides comprehensive information about platelet reactivity. This feedback system enables clinicians to identify patients with residual thrombotic risk who may require treatment adjustment, improving reliability in predicting thrombotic events through the combined assessment pattern rather than single-marker interpretation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for a more accurate assessment of residual platelet reactivity, identifying a subgroup of patients with increased prothrombotic potential despite apparent treatment efficacy, thereby enhancing the monitoring and prognosis of adverse cardiovascular events.
Implementation Method 1
using flow cytometry and specific monoclonal antibodies
Data Source
Figure 1A~1F
Figure 2
AI summary
Disclosed is a method for evaluating residual platelet thrombotic potential in patients undergoing antiplatelet treatment, which comprises determination in a patient's blood sample of vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) status and platelet tissue factor (TF) expression.